Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Nasdaq Composite reaching new highs, investors are closely monitoring developments in trade agreements ...

Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan ...